GLPwatch
Papers (10389)
Page 143 of 174, ranked by citation count.
- Individual Variability in the Cardiometabolic Response to Tirzepatide: Moving Beyond the Average.
- Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape.
- Is semaglutide cost-effective at closing the gap for Aboriginal and Torres Strait Islander Australians with cardiovascular disease and obesity without type 2 diabetes?
- Dapagliflozin restores odour-induced functional integration of primary olfactory cortex circuit but not olfactory-related regional brain activation in patients with type 2 diabetes: A 16-week randomised comparative study.
- Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
- Weekly journal scan: SURMOUNTing body weight regain with tirzepatide after successful lifestyle intervention.
- Semaglutide Slows Epigenetic Aging in People with HIV-associated lipohypertrophy: Evidence from a Randomized Controlled Trial.
- Effect of Tirzepatide on Heart Failure in Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Meta-Analysis.
- Missed Doses, Missed Opportunities: Readmission Due to GLP-1RA Interruption Inspires Algorithms to Improve Reinitiation of Therapy at Discharge.
- Nonmechanical Small Bowel Obstruction in a Patient on Zepbound Without a Surgical History: A Case Report.
- Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity.
- Protective anti-fibrotic effect of liraglutide and Pirfenidone combination therapy on liver fibrosis in rats: effects on autophagy and NLRP3 inflammasome.
- Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.
- The Effect of GLP-1 Receptor Agonists on Alanine Aminotransferase and Other Metabolic Parameters in Youths with Obesity: A Systematic Review and Meta-Analysis.
- Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: A retrospective real-world analysis (URISEMA study).
- 12-month outcomes of GLP - 1 in severe pediatric obesity: real-world data.
- Liraglutide Mitigates Renal Injury in Diabetic Kidney Disease by Suppressing Podocyte Cholesterol Accumulation Through mTOR/VMP1-Regulated Autophagy.
- Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis.
- Glucose-lowering effects of semaglutide compared with dulaglutide using professional continuous glucose monitoring in outpatients with type 2 diabetes mellitus: a pilot study.
- Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin.
- Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson's disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study.
- GLP-1 receptor agonists as pharmacological treatment for obesity after spinal cord injury: clinical considerations.
- CCK Response Deficiency in Synphilin-1 Transgenic Mice.
- Liraglutide in the management of obesity: real world data (Portugal).
- Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling.
- The Cascade System of Osmotic Homeostasis Regulation.
- Are glucagon-like peptide-1 (GLP-1) receptor agonists useful in treating Parkinson's disease (PD)? Does the clinical trial with lixisenatide add anything?
- Liraglutide ameliorates intrauterine adhesion by inhibiting NF-κb phosphorylation and reducing epithelial-mesenchymal transition.
- Efficacy and Safety of Pharmacological, Endoscopic, and Surgical Treatments for Obesity: A GRADE-Based Network Meta-Analysis.
- Bridging the Gap to Waitlist Activation: Semaglutide's Weight Loss Efficacy and Safety in Patients With Obesity on Dialysis Seeking Kidney Transplantation.
- NICE approves liraglutide for diabetic patients not achieving glucose control.
- Liraglutide use in pediatric type 2 familial partial lipodystrophy caused by LMNA mutation: a case report.
- Semaglutide Overdose in a Diabetic Patient: Suicidal Behavior and Multiorgan Failure.
- New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
- Glucagon-like peptide-1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity.
- Tirzepatide Outperforms Semaglutide in Head-to-Head Obesity Trial.
- GLP-1 receptor agonists and cardiovascular risk in routine clinical practice.
- Knowledge, attitude and practice toward liraglutide and semaglutide among endocrinology medical staff.
- Artificial intelligence and natural language processing of patient narratives to evaluate semaglutide for weight loss.
- Liraglutide attenuates aluminum chloride-induced Alzheimer's disease in rats by modulating the oxLDL/LPA/LPAR1 pathway.
- Fixing the food environment: beyond weight-loss drugs.
- Comparative Renal Safety of Tirzepatide and Semaglutide: An FDA Adverse Event Reporting System (FAERS)-Disproportionality Study.
- Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review.
- Tirzepatide (Mounjaro) - a novel Pharmacotherapeutic Agent for Obesity.
- An analysis of national news coverage of semaglutide for weight loss.
- Use of tirzepatide (Mounjaro) in type 2 diabetes management: an overview.
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.
- Effects of semaglutide on obstructive sleep apnea risk and outcomes in patients with obesity.
- Great Expectations: Semaglutide as Antidiabetic Weight Management in a Psychiatric Hospital.
- Do GLP-1 Receptor Agonists Care if You Have Heart Failure?
- Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes.
- Clinical Outcomes of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) and Glucagon-Like Peptide-1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (GLP-1/GIP RA) Exposures Presenting to the Emergency Department.
- [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
- Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation.
- Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes.
- Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6.
- Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.
- Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China.
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Alcohol Use Disorder: Current Evidence and Future Directions.
- After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes?